Which of the following is the gold standard medication-assisted treatment (MAT) for opioid use disorder in India?

Explanation

## Medication-Assisted Treatment for Opioid Use Disorder **Key Point:** Buprenorphine is the preferred and most widely available MAT agent in India, endorsed by NDDTC (National Drug Dependence Treatment Centre) and WHO guidelines for opioid use disorder management. ### Comparison of MAT Agents | Agent | Mechanism | Advantages | Disadvantages | Status in India | | --- | --- | --- | --- | --- | | **Buprenorphine** | Partial mu agonist | Low overdose risk, lower abuse potential, flexible dosing, safer in pregnancy | Ceiling effect on respiratory depression | **Gold standard, widely available** | | **Methadone** | Full mu agonist | Potent, long-acting | High overdose risk, requires daily clinic visits, drug interactions | Restricted, limited centers | | **Naltrexone** | Mu antagonist | No abuse potential, opioid-free | Poor compliance, precipitated withdrawal, no euphoria | Used for relapse prevention only | | **Tramadol** | Weak mu agonist + SNRI | Moderate analgesic | Not recommended for OUD, abuse potential, seizure risk | Not standard MAT | ### Why Buprenorphine is Preferred **High-Yield:** Buprenorphine has a **ceiling effect** on respiratory depression, making it safer than full mu agonists (methadone) in overdose scenarios. **Clinical Pearl:** Buprenorphine's partial agonist activity means: - Lower euphoria → lower abuse potential - Easier induction (no precipitated withdrawal if started correctly) - Flexible dosing schedules (can be given 2–3 times weekly) - Safer in pregnancy and lactation ### Indian Context **Mnemonic: BUPRENORPHINE BEST** — **B**etter safety profile, **U**niversal availability, **P**artial agonist, **R**educed overdose risk, **E**asier induction, **N**o daily clinic visits needed, **O**pioid-free alternative available, **R**elapse prevention, **P**regnancy-safe, **H**igh compliance, **I**ndian guideline-approved, **N**ational program support, **E**vidence-based. The National Drug Dependence Treatment Centre (NDDTC) and Ministry of Social Justice recommend buprenorphine as the first-line MAT in India [cite:NDDTC Guidelines]. [cite:Harrison 21e Ch 394; NDDTC Treatment Guidelines]